Ligand Acquires Royalty And Milestone Interest In Santen’s Ryjunea From Sydnexis For $23 Million

Sept. 22 (Reuters) - Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) said it has acquired the royalty and milestone interest in Santen’s Ryjunea® from Sydnexis for $23 million.

• Ligand said it will receive a tiered royalty on Ryjunea net sales in EMEA.
• The company said it bought the rights to royalty and milestone payments on Ryjunea in EMEA.
• Ligand said the acquired payment rights include a tiered low-double-digit to high-teens royalty on Ryjunea net sales in EMEA.